ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,025.17
      0.00%
      US Tech 100
      21,478.80
      1.00%
      Dow Jones
      42,581.78
      0.00%
      Brent Oil
      67.90
      -2.79%
      Bitcoin
      105,218.65
      -0.24%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Gilead Sciences Inc (GILD) Quote

      Gilead Sciences Inc

      Gilead Sciences Inc (GILD)

      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      Guild Esports Plc
      106.19
      -2.31
      (-2.13%)
      Closed June 23 4:00PM
      15 min delayed - Upgrade to Realtime
      106.75
      0.56
      ( 0.53% )
      Pre Market: 8:42AM
      15 min delayed - Upgrade to Realtime

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      106.75
      Bid
      106.80
      Ask
      107.00
      Volume
      6,346
      0.00 Day's Range 0.00
      66.01 52 Week Range 119.96
      Market Cap
      132.789B
      Previous Close
      106.19
      Open
      -
      Last Trade
      94
      @
      106.7
      Last Trade Time
      08:39:23
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      9,236,758
      Shares Outstanding
      1,243,929,121
      Dividend Yield
      2.96%
      PE Ratio
      275.17
      Earnings Per Share (EPS)
      0.39
      Revenue
      28.75B
      Net Profit
      480M

      About Gilead Sciences Inc

      Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.gilead.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $106.19. Over the last year, Gilead Sciences shares have traded in a share price range of $ 66.01 to $ 119.96.

      Gilead Sciences currently has 1,243,929,121 shares outstanding. The market capitalization of Gilead Sciences is $132.09 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 275.17.

      Ask ADVFN Intelligence (AI)

      Gilead Sciences (GILD) Options Flow Summary

      GILD Options Flow

      Overall Flow

      Bullish

      Net Premium

      190k

      Calls / Puts

      200.00%

      Buys / Sells

      91.67%

      OTM / ITM

      100.00%

      Sweeps Ratio

      0.00%

      GILD Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 17 2025
      GILD (-2.13%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 17 2025
      GILD (-2.13%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      June 16 2025
      GILD (-2.13%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      June 16 2025
      GILD (-2.13%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 11 2025
      GILD (-2.13%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 11 2025
      GILD (-2.13%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      June 11 2025
      GILD (-2.13%)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-3.54-3.20971982954110.29111.78105.350112948115107.93901486CS
      4-1.55-1.43120960295108.3113.5199105.35018789784109.4720461CS
      12-5.25-4.6875112114.7593.379236758105.88633463CS
      2613.7514.784946236693119.9688.578678064105.14450717CS
      5235.7550.352112676171119.9666.01758828595.272272CS
      15643.9469.957013214562.81119.9659.27698659882.43062373CS
      26031.848242.519939440774.9018119.9656.56749629374.79652849CS

      GILD - Frequently Asked Questions (FAQ)

      What is the current Gilead Sciences share price?
      The current share price of Gilead Sciences is $ 106.75
      How many Gilead Sciences shares are in issue?
      Gilead Sciences has 1,243,929,121 shares in issue
      What is the market cap of Gilead Sciences?
      The market capitalisation of Gilead Sciences is USD 132.09B
      What is the 1 year trading range for Gilead Sciences share price?
      Gilead Sciences has traded in the range of $ 66.01 to $ 119.96 during the past year
      What is the PE ratio of Gilead Sciences?
      The price to earnings ratio of Gilead Sciences is 275.17
      What is the cash to sales ratio of Gilead Sciences?
      The cash to sales ratio of Gilead Sciences is 4.59
      What is the reporting currency for Gilead Sciences?
      Gilead Sciences reports financial results in USD
      What is the latest annual turnover for Gilead Sciences?
      The latest annual turnover of Gilead Sciences is USD 28.75B
      What is the latest annual profit for Gilead Sciences?
      The latest annual profit of Gilead Sciences is USD 480M
      What is the registered address of Gilead Sciences?
      The registered address for Gilead Sciences is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
      What is the Gilead Sciences website address?
      The website address for Gilead Sciences is www.gilead.com
      Which industry sector does Gilead Sciences operate in?
      Gilead Sciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      NANano Labs Ltd
      $ 27.78
      (155.10%)
      		7.95M
      NKTRNektar Therapeutics
      $ 21.74
      (127.88%)
      		3.65M
      ONMDOneMedNet Corporation
      $ 0.6781
      (99.44%)
      		23.35M
      INMInMed Pharmaceuticals Inc
      $ 4.08
      (66.53%)
      		37.44M
      IBIOiBio Inc
      $ 1.00
      (40.37%)
      		33.01M
      UPXIUpexi Inc
      $ 3.90
      (-61.00%)
      		583.11k
      MAASMaase Inc
      $ 5.6997
      (-42.60%)
      		198.01k
      HYFMHydrofarm Holdings Group Inc
      $ 2.55
      (-34.45%)
      		29
      DFDVDeFi Development Corporation
      $ 16.31
      (-34.26%)
      		579.73k
      RBNERobin Energy Ltd
      $ 5.2781
      (-21.22%)
      		629.22k
      PSTVPlus Therapeutics Inc
      $ 0.2161
      (17.25%)
      		64.78M
      ADILAdial Pharmaceuticals Inc
      $ 0.24
      (-8.75%)
      		50.22M
      INMInMed Pharmaceuticals Inc
      $ 4.08
      (66.53%)
      		37.44M
      IBIOiBio Inc
      $ 1.00
      (40.37%)
      		33.01M
      HCTIHealthcare Triangle Inc
      $ 0.0327
      (5.48%)
      		27.85M

      GILD Discussion

      View Posts
      jondoeuk jondoeuk 2 days ago
      They are moving beyond quadruple edited to build a sextuple-edited CAR-T therapy for glioblastoma.
      👍️0
      TucsonPhil TucsonPhil 5 days ago
      https://www.cnbc.com/2025/06/18/fda-approves-gilead-hiv-prevention-injection-lenacapavir.html

      This should be great news, but from a financial, shareholder perspective, there are concerns about cost and availability, with U.S. government programs cutting funding for HIV prevention programs.
      👍️0
      jondoeuk jondoeuk 6 days ago
      I've heard that an MD Anderson team is developing an off-the-shelf IL-21 armoured CAR-NK cell therapy that will target EGFR and IL13Ra2 https://www.cell.com/cancer-cell/abstract/S1535-6108(24)00272-1

      They are also testing another off-the-shelf NK cell therapy with containing deleted of TGFBR2 and NR3C1 in recurrent glioblastoma. This makes the NKs resistant to tumour- and corticosteroid-induced immunosuppression, respectively. Going forward, they plan to test these NKs with Delta-24-RGD https://ascopubs.org/doi/10.1200/JCO.2017.75.8219

      When combined with NKs, they found that treatment with Delta-24-RGD altered the immunosuppressive tumour microenvironment and increased the recruitment, antitumour activity, survival, and memory of endogenous NKs as well.

      👍️0
      jondoeuk jondoeuk 6 days ago
      It will be interesting to see GILD's KITE-753 clinical data. The only difference between it (and KITE-363) is a reduced production time.

      However, based on preclinical data, KITE-753 exhibited higher expression of both CARs and increased proportion of CCR7+/CD45RA+ T-cells* compared to the KITE-363 benchmark.

      Also, KITE-753 exhibited enhanced cytokine production, enhanced proliferation, increased peripheral peak expansion, and superior antitumour efficacy compared to the KITE-363 benchmark.

      * CCR7+/CD45RA+CD4+ of ~60% vs ~5%, and CCR7+/CD45RA+CD8+ of ~80% vs ~15%. High circulating CCR7+ populations positively correlate with antitumour response https://www.nature.com/articles/s41591-020-1061-7
      👍️0
      jondoeuk jondoeuk 6 days ago
      Others https://www.oncologypipeline.com/apexonco/lyell-takes-jj-and-gilead
      👍️0
      jondoeuk jondoeuk 1 week ago
      An update https://www.oncologypipeline.com/apexonco/eha-2025-arcellx-still-hopes-safety-will-trump-efficacy
      👍️0
      jondoeuk jondoeuk 1 week ago
      The UPenn team have been developing this https://jitc.bmj.com/content/11/Suppl_1/A323
      👍️0
      jondoeuk jondoeuk 3 weeks ago
      One company is developing an off-the-shelf version https://www.kiragenbio.com/our-science
      👍️0
      jondoeuk jondoeuk 3 weeks ago
      ASCO: Kite's CAR-T passes lymphoma safety trial with flying colors https://www.fiercebiotech.com/biotech/asco-kites-car-t-passes-lymphoma-safety-trial-flying-colors
      👍️0
      jondoeuk jondoeuk 3 weeks ago
      Dual-target CAR T cell therapy slows growth of aggressive brain cancer https://medicalxpress.com/news/2025-05-dual-car-cell-therapy-growth.html
      👍️0
      BottomBounce BottomBounce 1 month ago
      Dr. Paul Marik:

      Hospital Would not allow me to Use Vitamin C, but wanted me to Use Remdesivir, Which Increases risk of Kidney Failure by 20X & increases Death by 4%

      The Federal Government will give Hospitals 20% Bonus if you prescribe Remdesivir pic.twitter.com/Rk0F024jBf— Asher Press (@AsherPress) June 19, 2024 $GILD
      👍️0
      fink fink 2 months ago
      Yulp.
      New Management style = Company first lay offs.
      AIDS is cured.
      HepC is cured
      Cancer is a nothing burger but a management waste of money
      All they got is Prep.

      I'm thinking a golden opportunity to short this top heavy pig. They got nothing in the pipeline but cost cutting.
      👍️0
      Greedy G Greedy G 4 months ago
      ~sold the 2/14 $108 calls @.20c 
      👍️0
      Greedy G Greedy G 4 months ago
      ~bought the 2/14 $108 calls @.05c ahead of earnings today 
      👍️0
      fink fink 5 months ago
      Looks like the National Sales meeting in Vegas, has employees dumping after this high.
      Management must not be painting much hope for the future.

      I can't wait to hear what the pump is to keep employees from bailing out.
      👍️0
      jondoeuk jondoeuk 7 months ago
      They now add an investigational HIV vaccine to its portfolio https://www.fiercebiotech.com/biotech/gilead-buys-hiv-vaccine-spanish-biotech-following-success-clinical-collab

      Data on the vaccine in combination with vesatolimod https://www.ddw-online.com/hiv-combination-regimen-could-lead-to-viral-remission-22215-202302/
      👍️0
      jondoeuk jondoeuk 7 months ago
      Based on recent data*, I would have thought that getting KITE-509 into the clinic (for GPC3+ solid tumours, not just 3L+ HCC) would be a priority.

      * https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4019 https://www.nature.com/articles/s41586-024-08261-8
      👍️0
      fink fink 7 months ago
      CEO is talking now.
      The stock is selling off on great words.
      Go figure! 6month Prep shot is a game changer. Generics are already being made for third world nations. These guys are going to eradicate AIDS.

      They should be allowed to make a buck or two.
      I want $250 a share please, I've held it way too long.
      👍️0
      Monksdream Monksdream 8 months ago
      GILD, 10Q 11/6
      👍️0
      Monksdream Monksdream 8 months ago
      GILD a new 52 week high
      👍️0
      Monksdream Monksdream 8 months ago
      GILD new 52=week high
      👍️0
      jondoeuk jondoeuk 8 months ago
      Two years later, and here are some of my takeaways...

      - They know they need to expand into more (rural) areas and that might include pre-built clean rooms. Slides 21-26 show how difficult it is to drive uptake further. "Majority of future growth expected from establishing new ATC's in community." These centres need to establish new relationships with others for apheresis, local ER's for (CRS/ICANS) emergencies and even local freezer storage requirements, which is it's own thing. So much goes into treatment that has nothing to do with manufacturing.

      - Forgot ZUMA-12 data was that good. A 86% CR rate and 81% three-year survival from 1L patients. Not sure how to compare that to later line trials, but decades from now, let's hope we are at the point we treat this front line (vs SOC now). Kite said their COGS is
      👍️0
      jondoeuk jondoeuk 8 months ago
      ''There have been more than 250 HIV vaccine trials, most of them early-stage, looking at whether the vaccine is safe and whether we mount an immune response following vaccination. There have been very few vaccine trials—10 or so—that have advanced to the point of looking at efficacy. Of those, one showed 31% efficacy at 42 months. That was the most promising trial, but the efficacy fell off very quickly, and it was only 31% and only against clade B. Whether that would translate to the other clades is not clear.'' https://publichealth.jhu.edu/2022/why-dont-we-have-an-hiv-vaccine
      👍️0
      jondoeuk jondoeuk 8 months ago
      How the hell is Dan O'Day still making 26 mil? A monkey throwing dart would have been better than this dimwit— Jack Shaw (@JackSha90859576) October 19, 2024
      👍️0
      TechandBio TechandBio 9 months ago
      Wants to go higher!

      $GILD
      👍️0
      Monksdream Monksdream 9 months ago
      GILD approaching a 52 week high
      👍️0
      north40000 north40000 9 months ago
      Featured on CNBC-TV this morning, 8:40 a.m. time frame.
      👍️0
      TechandBio TechandBio 11 months ago
      NICE!

      clutch stock with a disruptive cure prevention vaccine for HIV people would rather take 2 shots a year not to get HIV then taking oral pills for treatment!

      $GILD
      👍️0
      TechandBio TechandBio 11 months ago
      Adding shares and calls under $80..00

      HIV Cure Vaccine is a big deal data is incredible flawless. Oncology pipeline is building nicely.



      $GILD
      $GILD
      👍️0
      midastouch017 midastouch017 11 months ago
      Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors

      https://finance.yahoo.com/news/compugen-announces-fda-clearance-ind-110000034.html

      FDA clearance triggers a $30 million milestone payment from Gilead
      👍️0
      Monksdream Monksdream 11 months ago
      GILD under $100
      👍️0
      TechandBio TechandBio 11 months ago
      Target is $100-$120 by Q2 2025

      $GILD
      👍️0
      TechandBio TechandBio 11 months ago
      HIV Prevention CURE Shot 2x a year

      Great growing oncology pipeline!

      my $80 vertical Calls from last week are looking golden!

      $GILD
      👍️0
      north40000 north40000 1 year ago
      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

      "Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
      👍️0
      north40000 north40000 1 year ago
      How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
      👍️0
      jondoeuk jondoeuk 1 year ago
      There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
      👍️0
      jondoeuk jondoeuk 1 year ago
      A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
      👍️0
      jondoeuk jondoeuk 1 year ago
      They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
      👍️0
      jondoeuk jondoeuk 1 year ago
      ''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

      https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
      👍️0
      jondoeuk jondoeuk 1 year ago
      The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

      Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

      ''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
      👍️0
      jondoeuk jondoeuk 1 year ago
      The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
      👍️0
      jondoeuk jondoeuk 1 year ago
      IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
      👍️0
      jondoeuk jondoeuk 1 year ago
      Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
      👍️0
      jondoeuk jondoeuk 1 year ago
      Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
      👍️0
      jondoeuk jondoeuk 1 year ago
      I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
      👍️0
      jondoeuk jondoeuk 1 year ago
      Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
      👍️0
      Monksdream Monksdream 1 year ago
      GILD new 52 week high
      👍️0
      jondoeuk jondoeuk 2 years ago
      Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

      It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
      👍️0
      jondoeuk jondoeuk 2 years ago
      Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

      There have been a number of these over the years, but nothing seems to come of them
      👍️0
      jondoeuk jondoeuk 2 years ago
      The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

      If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
      👍️0

      Your Recent History

      NASDAQ
      GILD
      Gilead Sciences
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads